Details

Autor(en) / Beteiligte

• Mathur, Manoj
• Ratnam, P
• Saikumar, S
• John, Manuel
• Ravishankar, Siddharth
• Dinesh, M
• Chandil, Priya
• Pahuja, Kishore
• Cherlikar, Vidya
• Wadhwani, Sunny
• Bendale, Pankaj
• Hazari, Ajit
• Mishra, Rajesh
• Deshmukh, Susheel
• Achlerkar, Rahul
• Shah, Devang
• Hingorani, Chanda
• Shah, Kaivan
• Topiwala, Pratik
• Jani, Sheetal
• Rana, Viral
• Majumdar, Nilay
• Chakrabarti, Debasis
• Dey, Rituparna
• Halder, Debabrata
• Choudhury, Sumit
• Kumar, Ajeet
• Das, Sasmita
• Nanda, Ashok
• Kumar, Vidya
• Dubey, Rama
• Kamdar, Gulam
• Pandey, Alka
• Kishanpuria, Sheetal
• Srivastava, Rajat
• Singh, Parul
• Verma, Sunil
• Sharma, Neha
• Gupta, Rajeev

Titel

Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety

Ist Teil von

• Indian journal of ophthalmology, 2023-06, Vol.71 (6), p.2500-2503

Ort / Verlag

India: Wolters Kluwer India Pvt. Ltd

Erscheinungsjahr

2023

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Purpose: Glaucoma is the second leading cause of blindness worldwide, affecting more than 64 million people aged 40-80. The best way to manage primary open-angle glaucoma (POAG) is by lowering the intraocular pressure (IOP). Netarsudil is a Rho kinase inhibitor, the only class of antiglaucoma medications that reorganizes the extracellular matrix to improve the aqueous outflow through the trabecular pathway. Methods: An open-label, real-world, multicentric, observation-based 3-month study was performed for assessing the safety and ocular hypotensive efficacy of netarsudil ophthalmic solution (0.02% w/v) in patients with elevated IOP. Patients were given netarsudil ophthalmic solution (0.02% w/v) as a first-line therapy. Diurnal IOP measurements, best-corrected visual acuity, and adverse event assessments were recorded at each of the five visits (Day-1: screening day and first dosing day; subsequent observations were taken at 2 weeks, 4 weeks, 6 weeks, and 3 months). Results: Four hundred and sixty-nine patients from 39 centers throughout India completed the study. The mean IOP at baseline of the affected eyes was 24.84 ± 6.39 mmHg (mean ± standard deviation). After the first dose, the IOP was measured after 2, 4, and 6 weeks, with the final measurement taken at 3 months. The percentage reduction in IOP in glaucoma patients after 3 months of once-daily netarsudil 0.02% w/v solution use was 33.34%. The adverse effects experienced by patients were not severe in the majority of cases. Some adverse effects observed were redness, irritation, itching, and others, but only a small number of patients experienced severe reactions, as reported in a decreasing order: redness > irritation > watering > itching > stinging > blurring. Conclusion: We found that netarsudil 0.02% w/v solution monotherapy when used as the first-line treatment in primary open-angle glaucoma and ocular hypertension was both safe and effective.